All News
Psoriatic Arthritis and Pregnancy
Mar 20, 2023
At RheumNow Live this weekend, Dr. Christina Chambers, an epidemiologist at the University of California San Diego and the principal investigator of MotherToBaby Pregnancy Studies, reviewed the available data on psoriatic arthritis and pregnancy. There is little evidence at this time that pregnancy affects PsA, though studies reliably demonstrate increase in disease activity in the post-partum period in both skin and joint disease.
Read Article
@RheumNow's review of new drug approvals during 2022 at #RNL2023 https://t.co/IgndlG6lOI
Mar 19, 2023
Biosimilars are coming!
Multiple adalimumab biosimilars this year
- will we see a dramatic price difference?
@RheumNow #RNL2023 https://t.co/8vdtXtEGOO
Mar 19, 2023
Biosimilar to biosimilar switching of Infliximab , @RheumNow Kavanaugh #RNL2023
Communications is a key always.
Discuss with your patient always, and show them the data. https://t.co/d7Nq6LoJYQ
Mar 19, 2023
Risk of adverse outcomes in PsA pregnancies
More pre eclampsia
More Cesarian section
More preterms
By Dr.Chambers #RNL2023 @RheumNow https://t.co/LRiSSpv4Yj
Mar 19, 2023
Dr. Eric Ruderman with an excellent review of the JAK/STAT pathway especially for PsA treatment
@RheumNow #RNL2023 https://t.co/kNDouZ4kCV
Mar 19, 2023
#RNL2023 Year in Review
COMPLETE-PsA: DMARDs for PsA!
LEF+MTX better than MTX alone, 78 total patients
PASDAS at week 16: 59% for MTX+LEF vs 34% MTX+PBO
More treatment discontinuations (10 vs 3) in combo group due to GI intolerance
@RheumNow https://t.co/3Al8PQmNli
Mar 19, 2023
Check out MothertoBaby fact sheets by the NIH and LactRX (by mother to baby) app for pregnancy, disease, and medications. Dr. C. Chambers highlighted this today at #RNL2023 @RheumNow
Mar 19, 2023
#RNL2023 Year in Review
Male response better than female response in patients with PsA in SELECT-PsA evaluating UPA/ADA.
More targeted studies needed
@RheumNow https://t.co/Z3kbM0e9A0
Mar 19, 2023
#RNL2023 Year in Review
BE COMPLETE: P3 trial Bimekizumab for PsA in TNF inadequate responses at 16 weeks
160 mg BKZ SQ q4w vs PBO
ACR50 43%, PBO 7%
PASI 1000: BKZ 58.5% vs PBO 4.5%
Safety: oral candidiasis: 2.6% BKZ vs PBO 0%
@RheumNow https://t.co/bW00Wg6Cnf
Mar 19, 2023
Talk to me about candidiasis. BKZ showed increased safety signals for candida infections. I fear infxns may be under reported (after approval and in use) if patients see other physicians for treatment vs their rheumatologist/derm. Thoughts on this signal? #RNL2023 @rheumnow https://t.co/UPA5oP9G49
Mar 19, 2023
TYK2 in plaque psoriasis By Eric Ruderman #RNL2023 @RheumNow
Safer?
No lab monitoring
And it works https://t.co/9Woen2q4hZ
Mar 19, 2023
TYK2 signalling Vs JAK signalling summary
#RNL2023 https://t.co/0VNBiEc6jq
Mar 19, 2023
Approach to pregnancy in patients with PsA , By Dr.Chambers #RNL2023 @RheumNow https://t.co/8tSz7qbmQU
Mar 19, 2023
Prevalence of PsA in women of reproductive age, By Dr.Chambers #RNL2023 @RheumNow https://t.co/hB6QQtz7fw
Mar 19, 2023
Dr. Laura Coates on PsA treatment:
- Applying treat to target associated with better quality of life
- low disease activity is a reasonable target
Do you use PROs in managing your PsA pts? Perhaps we should
@RheumNow #RNL2023 https://t.co/36n1Cp5jtP
Mar 19, 2023
Why do PROs matter? @DrLauraCoates reviewed this slide regarding the increased survival curve in end-stage cancer patients when we monitor PROs. @RheumNow #RNL2023 https://t.co/JfHNBKJGRl
Mar 19, 2023
29 pts w/PsA Sine Psoriasis: 16F/13M, mean age 45 yrs w/ PsA ~6.2 yrs. 54% had 1st-degree relatives with PsA. 66% had DIP arthritis, 39% polyarticular, 36% oligoarticular, 25% were axial. Nail findings seen in 89%, enthesitis 59%, dactylitis 62% https://t.co/MlnIzGBzn0 https://t.co/8hHE3Yv8UE
Links:
Mar 18, 2023
Preterm deliveries in PsA pregnancies were more pronounced with 1- first pregnancy.
2- Discontinuation of biologic prior to pregnancy.
By Dr.Chambers #RNL2023 @RheumNow https://t.co/CxZh0ak4l0
Mar 18, 2023
Neonatal outcomes:
Small for gestational age more common with an Adjusted OR off 2.42 and statistically significant.
By Dr.Chambers #RNL2023 @RheumNow https://t.co/NFMAEROEEM
Mar 18, 2023